NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / V.F. Corporation (NYSE:VFC)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly informed investors that the Company’s revenue outlook was reliable while also minimizing the risk of seasonality and macroeconomic fluctuations. Notably, the Company failed to notify investors that significant reset actions would be necessary to return the Vans brand to growth, causing significant setbacks to Van’s revenue growth trajectory.
If you are a VFC investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Fluor Corporation (NYSE:FLR)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly failed to inform investors of numerous issues in infrastructure projects, including subcontractor design flaws, cost escalations, and timeline setbacks.
If you are an FLR investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Cytokinetics, Incorporated (NASDAQ:CYTK)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly made materially false and misleading statements regarding the timeline for the New Drug Application ("NDA") submission and approval process for aficamten.
If you are a CYTK investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
Jasper Therapeutics, Inc. (NASDAQ:JSPR)
Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with allegations that the Company made false and/or misleading statements and/or failed to disclose material information. Specifically, the Company allegedly failed to disclose that (1) Jasper lacked the controls and procedures necessary to ensure that third-party manufacturers that it relied upon were manufacturing products in full accordance with cGMP regulations and otherwise were suitable for use in clinical trials; (2) this increased the likelihood that results of ongoing studies would be confounded, thus negatively impacting the regulatory and commercial prospects of the Company’s products; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; and (4) as a result, the Company’s business and/or financial prospects were overstated.
If you are a JSPR investor, or possess relevant information and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at info@lifshitzlaw.com.
ATTORNEY ADVERTISING.© 2025 Lifshitz Law PLLC. The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact:
Joshua M. Lifshitz, Esq.
Lifshitz Law PLLC
Phone: 516-493-9780
Facsimile: 516-280-7376
Email: jlifshitz@lifshitzlaw.com
SOURCE: Lifshitz Law Firm
View the original press release on ACCESS Newswire
COMTEX_470232460/2457/2025-11-13T14:59:30